Sandoz launches an authorized generic of key oncology product VIDAZA®

Princeton, New Jersey, September 23, 2013 – Sandoz today announced the US launch of azacitidine for injection, an authorized generic version of Celgene’s VIDAZA®. Azacitidine for injection is indicated to treat myelodysplastic syndrome (MDS), a bone marrow disease formerly known as pre-leukemia.1 “Sandoz is pleased to make this affordable, high-quality oncology product available to patients […]